Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.68 |
| ▸ | CES1 | P23141 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | JAK1 | P23458 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462782 | 0.82 | CES2 (0.68) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL546633 | 0.82 | CES2 (0.68) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL26903783 | 0.82 | CES2 (0.68) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL7220072 | 0.81 | CES2 (1.00) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL30250451 | 0.81 | CES2 (0.74) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL941698 | 0.81 | CES2 (0.74) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL31032483 | 0.81 | CES2 (1.00) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| SCHEMBL29613672 | 0.81 | CES2 (0.74) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL8358165 | 0.80 | CES2 (0.65) | CES2CES1SMN1; SMN2KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL22558829 | 0.80 | CES2 (0.65) | CES2CES1SMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110078717-B | Bis-benzofuran-benzimidazole salt compound with anti-tumor activity and preparation method thereof | 红河学院 | 2022-04-26 | — | — | CN | claimed |
| CN-109053847-B | 17 β -imidazolidinyl bromide-dehydroepiandrostane derivative and preparation method and application thereof | 云南大学 | 2020-05-19 | — | — | CN | claimed |
| CN-106916144-B | N-alkyl substituted indole-imidazole salt compound and preparation method thereof | 云南民族大学 | 2020-05-05 | — | — | CN | claimed |
| CN-106543147-A | A kind of substituted carbazole-imidazole salts or benzimidazole salt compound and preparation method thereof | 云南大学 | 2017-03-29 | — | — | CN | claimed |
| CN-106478653-A | Isosorbide imidazole salt compound and preparation method thereof | 云南民族大学 | 2017-03-08 | — | — | CN | claimed |
| CN-102617445-B | Photosensitive compositions, curable compositions, novel compounds, photopolymerizable compositions, color filters, and planographic printing plate precursors | FUJIFILM CORP | 2015-02-18 | — | — | CN | claimed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-20240241442-A1 | Positive Resist Material And Patterning Process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-12013639-B2 | Positive resist material and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20240192591-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
| CN-114660896-B | Composition for forming silicon-containing resist underlayer film, pattern forming method, and silicon compound | 信越化学工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| US-12001138-B2 | Composition for forming silicon-containing resist underlayer film and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-06-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4564620-A | 5,6,7,-Trinor-4,8-inter-m-phenylene PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0024943-B1 | 5,6,7-TRINOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TORAY INDUSTRIES, INC. (JP) | 1983-08-17 | — | — | EP | disclosed |
| EP-0060640-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1982-09-22 | — | — | EP | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CES2 351/4885CES1 154/4885SMN1; SMN2 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.